fashion -WSS

fashion

author：knowledge 2025-09-30 00:38:41 - browse：537

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： What drug price negotiations mean for Medicare Part D

WSS

Amazon on where the company's health care bets are headed next

Stem cell treatment guidelines are released by FDA

Fatty liver disease was alleviated by Lilly’s ‘triple

The biotech scorecard for Q3: 15 stock

How to protect patients from sexual assault

Hubble vs. James Webb telescope images: See the difference

explore

fashion

Wikipedia

Bright Health sells Medicare Advantage business to Molina

UpToDate has a racism problem: Dr. Stanley Goldfarb

Medicare details structure of new drug price negotiation program

ALS advocates say criticism of new drugs misses bigger picture

Duchenne breakthrough therapy leaves behind pioneering families

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Novavax promises a turnaround & Lilly roils the obesity market

AstraZeneca lung cancer study comes in below expectations

Apple is now the first public company to be valued at $3 trillion

Listen: Biogen's potential pivot, & Illumina's next chapter

entertainment

Snackable artificial intelligence, expert AI, and the pharma industry

How Robert F. Kennedy Jr. distorted vaccine science

Canadians with cystic fibrosis outlive Americans by a decade

What affirmative action's end means to a medical student

What drug price negotiations mean for Medicare Part D

Being 'nonadherent' patient made me a more empathetic doctor

hotspot

explore

hotspot

Wikipedia